Ironwood Pharmaceuticals vs Protagonist Therapeutics
IRWD and PTGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRWD and PTGX compare
Protagonist Therapeutics is the larger company, worth 16 times as much as Ironwood Pharmaceuticals ($9.4B against $598M).
On earnings, Ironwood Pharmaceuticals is cheaper: it trades at 4.7× trailing earnings, against 141× for Protagonist Therapeutics.
Protagonist Therapeutics grew revenue faster over the last twelve months (34.8% versus 26.2% for Ironwood Pharmaceuticals).
Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with 29.4% at Protagonist Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRWD | PTGX |
|---|---|---|
| Size and price | ||
| Market cap | $598M | $9.4B |
| Share price | $3.62 | $144.85 |
| Change, 1 year | 135% | 88.9% |
| Change, 5 years | −71.9% | 329% |
| Beta (5Y) | 0.60 | 0.77 |
| Employees | 100 | 132 |
| StockData Score | ||
| Total score | 12 | 12 |
| Valuation score | 6 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 4.7× (better) | 141× |
| P/S | 1.5× (better) | 33.2× |
| P/B | – | 11.1× |
| EV/EBITDA | 2.2× (better) | 143× |
| P/FCF | – | 71.8× |
| FCF yield | – | 1.4% |
| Fair value | $13.20 | $36.28 |
| Margin of safety | 72.6% (better) | −299% |
| Growth | ||
| Revenue growth (TTM) | 26.2% | 34.8% (better) |
| Revenue growth, 5Y average | −5.3% | 10.0% (better) |
| Net income growth (TTM) | – | 59.3% |
| EPS growth (TTM) | – | 47.1% |
| EPS growth, 5Y average | −25.6% | – |
| Profitability | ||
| Operating margin | 60.1% (better) | 20.7% |
| Net margin | 33.4% (better) | 29.4% |
| FCF margin | – | 46.3% |
| Return on equity | – | 11.0% |
| Return on invested capital | – | 73.3% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 7.2× | – |
| Current ratio | 6.06 | 21.71 (better) |
| Altman Z-score | −2.19 | 128.91 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.2% | 117% |
| Held by insiders | 16.0% | 1.7% |
| Insider net buying, 12 months | −$22.6M (better) | −$86.9M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 11.2% | 14.7% |
Go deeper
- IRWD stock overview
- IRWD income statement
- IRWD valuation and score
- PTGX stock overview
- PTGX income statement
- PTGX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.